Currently Viewing:
Supplements Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin
Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors
Murray Epstein, MD; Nancy L. Reaven, MA; Susan E. Funk, MBA; Karen J. McGaughey, PhD; Nina Oestreicher, PhD; John Knispel, MD
eAPPENDIX 1. ICD-9 CODES USED FOR CLASSIFICATION OF COMORBIDITIES
Currently Reading
eAPPENDIX 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR DRUGS AND MAXIMUM DOSE LEVELS
Participating Faculty: Evaluation of the Treatment Gap Between Clinical Guidelines and the Utilization of Renin-Angiotensin-Aldosterone System Inhibitors

eAPPENDIX 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR DRUGS AND MAXIMUM DOSE LEVELS

eAPPENDIX 2. RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITOR DRUGS AND MAXIMUM DOSE LEVELS

Evaluated renin-angiotensin-aldosterone system (RAAS) inhibitor drugs and their maximum doses, listed in descending order of observed frequency at index: lisinopril, 40 mg; losartan, 100 mg; valsartan, 320 mg; benazepril, 80 mg; olmesartan, 40 mg; enalapril, 40 mg; spironolactone, 200 mg; irbesartan, 300 mg; ramipril, 10 mg; quinapril, 80 mg; telmisartan, 80 mg; candesartan, 32 mg; captopril, 450 mg; fosinopril, 40 mg; trandolapril, 8 mg; moexipril, 30 mg; aliskiren, 300 mg; eplerenone, 100 mg; perindopril, 8 mg; eprosartan, 800 mg; azilsartan, 80 mg.

Aliskiren/valsartan formulated 150 mg-160 mg (a partial dose of each of 2 RAAS inhibitor drugs) was considered a partial dose (submaximum).
 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up